FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2970291468> ?p ?o ?g. }

• W2970291468 endingPage "1872" @default.
• W2970291468 startingPage "1872" @default.
• W2970291468 abstract "Abstract Introduction Patients with myeloma are at increased risk of venous thromboembolism (VTE) and arterial thrombosis, particularly when treated with immunomodulatory drugs (IMiDs) such as thalidomide or lenalidomide. The optimal approach to prevent such potentially fatal complications has not been determined. Despite routine thromboprophylaxis with aspirin, low molecular weight heparin (LMWH) or warfarin, thrombosis rates of thrombosis of 2-8% are reported in the literature. Current agents have limited efficacy with significant associated burdens such as repeated INR monitoring or subcutaneous administration. Direct oral anticoagulants are promising due to their convenience and effectiveness in preventing VTE in other settings. They have not been extensively studied in myeloma therapy. Our baseline audit of 82 consecutive myeloma patients treated with IMiD-containing regimens and receiving thromboprohylaxis with aspirin had VTE rates of 11%. Of 31 patients treated with heparins 6.5% had VTE. These rates are consistent with data in the literature. Apixaban is cheaper than LMWH therapy in our centre.In November 2014 our policy was changed such that apixaban became standard thromboprophylaxis; the effect of this change is reported here. Aim Assess the safety and efficacy of apixaban as thromboprophylaxis in patients with multiple myeloma undergoing first line therapy with IMID-containing regimens. Method Consecutively presenting patients between 1st November 2014 and 31st December 2016 with multiple myeloma undergoing first-line therapy with IMiD-containing regimens were included in this retrospective study. All patients received apixaban 2.5mg twice daily for the first 4 months of therapy or until treatment cessation. Patients with severe renal failure (CrCl Results 70patients were identified. 45 (64%) were male, the median age was 66 years, range 43-86. Previous thrombosis: 2 PE, 1 stroke, 1 TIA, 3 myocardial infarction. Treatment (n): Cyclophosphamide-Thalidomide-Dexamethasone (19), Bortezomib-Thalidomide-Dexamethasone (27), Lenalidomide-Dexamethasone (3), Carfilzomib-Cyclophosphamide-Lenalidomide-Dexamethasone (8), Melphalan-Prednisolone-Thalidomide (n=9), Lenalidomide-Cyclophosphamide-Dexamethasone (4). There were no DVTs or PEs within 6 months of treatment initiation. Two patients (2.9%) had arterial thrombosis. One patient had a non-haemorrhagic stroke at day 19 with no identified embolic source and she had no cardiovascular comorbidities. One patient had a non-ST elevation myocardial infarction at day 23 with no previous diagnosis of ischaemic heart disease. He had stopped both thalidomide and apixaban 21 days previously due to drug-induced rash. One patient (1.4%) had major bleeding. He had melaena during his 4th cycle of MPT that resolved on apixaban cessation. His platelet count had dropped to 21x10^9/L during this episode. He required hospital admission for blood transfusion, but no bleeding point was identified at endoscopy. Conclusion - We studied the use of apixaban for preventing IMiD-induced thrombosis in front line myeloma therapy. Rates of thrombosis appear to be very low with no cases of VTE identified and only 2 cases of arterial thrombosis. There was one episode of major bleeding in a patient with coexistent thrombocytopenia. These toxicity rates compare favourably to historical and published data with other anticoagulants. The drug is suitable for ambulatory treatment even in frail patients, and avoids the logistical and acceptability problems of subcutaneous injection of LMWH. Apixaban appears to be an attractive and safe option for thromboprophylaxis in this setting. Disclosures No relevant conflicts of interest to declare." @default.
• W2970291468 created "2019-09-05" @default.
• W2970291468 creator A5000779016 @default.
• W2970291468 creator A5070032224 @default.
• W2970291468 creator A5071354077 @default.
• W2970291468 creator A5087195871 @default.
• W2970291468 date "2017-12-07" @default.
• W2970291468 modified "2023-09-29" @default.
• W2970291468 title "Apixaban Is Safe and Effective Thromboprophylaxis in Myeloma Patients Treated with Immunomodulatory Therapy" @default.
• W2970291468 doi "https://doi.org/10.1182/blood.v130.suppl_1.1872.1872" @default.
• W2970291468 hasPublicationYear "2017" @default.
• W2970291468 type Work @default.
• W2970291468 sameAs 2970291468 @default.
• W2970291468 citedByCount "0" @default.
• W2970291468 crossrefType "journal-article" @default.
• W2970291468 hasAuthorship W2970291468A5000779016 @default.
• W2970291468 hasAuthorship W2970291468A5070032224 @default.
• W2970291468 hasAuthorship W2970291468A5071354077 @default.
• W2970291468 hasAuthorship W2970291468A5087195871 @default.
• W2970291468 hasConcept C126322002 @default.
• W2970291468 hasConcept C141071460 @default.
• W2970291468 hasConcept C177713679 @default.
• W2970291468 hasConcept C2776063141 @default.
• W2970291468 hasConcept C2776301958 @default.
• W2970291468 hasConcept C2776364478 @default.
• W2970291468 hasConcept C2777628954 @default.
• W2970291468 hasConcept C2778524551 @default.
• W2970291468 hasConcept C2778661090 @default.
• W2970291468 hasConcept C2779161974 @default.
• W2970291468 hasConcept C2780638905 @default.
• W2970291468 hasConcept C2780868729 @default.
• W2970291468 hasConcept C71924100 @default.
• W2970291468 hasConceptScore W2970291468C126322002 @default.
• W2970291468 hasConceptScore W2970291468C141071460 @default.
• W2970291468 hasConceptScore W2970291468C177713679 @default.
• W2970291468 hasConceptScore W2970291468C2776063141 @default.
• W2970291468 hasConceptScore W2970291468C2776301958 @default.
• W2970291468 hasConceptScore W2970291468C2776364478 @default.
• W2970291468 hasConceptScore W2970291468C2777628954 @default.
• W2970291468 hasConceptScore W2970291468C2778524551 @default.
• W2970291468 hasConceptScore W2970291468C2778661090 @default.
• W2970291468 hasConceptScore W2970291468C2779161974 @default.
• W2970291468 hasConceptScore W2970291468C2780638905 @default.
• W2970291468 hasConceptScore W2970291468C2780868729 @default.
• W2970291468 hasConceptScore W2970291468C71924100 @default.
• W2970291468 hasLocation W29702914681 @default.
• W2970291468 hasOpenAccess W2970291468 @default.
• W2970291468 hasPrimaryLocation W29702914681 @default.
• W2970291468 hasRelatedWork W1981572393 @default.
• W2970291468 hasRelatedWork W2021677396 @default.
• W2970291468 hasRelatedWork W2030742912 @default.
• W2970291468 hasRelatedWork W2034057495 @default.
• W2970291468 hasRelatedWork W2194597658 @default.
• W2970291468 hasRelatedWork W2467367505 @default.
• W2970291468 hasRelatedWork W2554617582 @default.
• W2970291468 hasRelatedWork W25568880 @default.
• W2970291468 hasRelatedWork W2560150554 @default.
• W2970291468 hasRelatedWork W2562085850 @default.
• W2970291468 hasRelatedWork W2567391556 @default.
• W2970291468 hasRelatedWork W2588067903 @default.
• W2970291468 hasRelatedWork W2588072689 @default.
• W2970291468 hasRelatedWork W2589687051 @default.
• W2970291468 hasRelatedWork W2946807904 @default.
• W2970291468 hasRelatedWork W2955994566 @default.
• W2970291468 hasRelatedWork W2986460858 @default.
• W2970291468 hasRelatedWork W2992938947 @default.
• W2970291468 hasRelatedWork W3108546633 @default.
• W2970291468 hasRelatedWork W3190747619 @default.
• W2970291468 hasVolume "130" @default.
• W2970291468 isParatext "false" @default.
• W2970291468 isRetracted "false" @default.
• W2970291468 magId "2970291468" @default.
• W2970291468 workType "article" @default.